According to the current analysis of Reports and
Data, the global Biosimilars
market was valued at USD 5.10 Billion in 2018 and is
expected to reach USD 44.56 Billion by year 2026, at a CAGR of 30.8%.
Biosimilar are alternatives to existing patented, and approved biologicss and
possess similar medicinal properties as compared to the original biologics. The
biosimilars vary a little from original biologics in terms of structure but
must have similar safety and efficacy as compared to the originator biologics.
Biosimilars development does not require Phase II clinical trial for approval
and the focus is put on determination of ‘biosimilarity’ to the reference
originator biologics. Thus it has much reduced clinical development timelines
and reduced product costs as compared to use of original biologics.
The global market is driven by various of factors
such as global prevalence of target disease prevalence across the globe, launch
of biosimilars by various market players, favorable investments scenario, and
upcoming patent expiry.
The Biosimilars market is characterized by presence
of significant number of pharmaceutical giants as well as emerging players
operating across the globe. Additionally, availability of research fundings,
demand for cheaper biologics alternative and favorable regulatory scenario in Europe
and Asia pacific is propelling the market in these regions. However, some
regions such as U.S are facing slow adoption of biosimilars with first
biosimilar approved in 2015 for Sandoz’s Zarxio (filgrastim), and 3, 5, and 7,
biosimilars approved by FDA in 2016, 2017, and 2018, respectively..
Further key findings from the report suggest
- Biosimilars market is growing at a CAGR of 2%
in Asia Pacific followed by North America and Europe, with 21.0% and 31.4%
CAGR, respectively. High chronic disease prevalence across the globe is
the key factor to accelerate the market growth during forecast period across
all regions.
- As of 2018, Recombinant Non-glycosylated
Proteins is the dominating Biosimilars which holds over 60% of the global
market. European regional market is the chief revenue generating source
for this product segment, followed by North America and Asia-Pacific
regions.
- Recombinant Glycosylated Proteins is expected
to be the fastest growing market segment during forecast period 2019-2026
with a CAGR of 33.4%. However, regulatory obstacles and manufacturing
complexity are major challenge for the market growth of this market
segment.
- Recombinant Peptides segment was estimated to
account for USD 501.00 million in 2018 and is expected to grow reach USD
4.38 Billion by year 2026.
- Asia Pacific is expected to account for the
32.8% of the global Biosimilars market. Developing nations such China, and
India are likely to witness high growth.
- Some regions such as U.S. and Latin America
are facing slow adoption of biosimilars due to stringent regulatory
framework..
- Key participants include Amgen, Biocon, Celltrion,
Dr. Reddy's Laboratories, Mylan, Pfizer, Samsung Biologics, Sandoz, Stada
Arzneimittel, and Teva Pahrmaceutical .
For the purpose of this report, Reports and Data
has segmented the Biosimilars market on the basis of type, disease type, and
region:
Type (Revenue, USD Million; 2016–2026)
- Recombinant Non-glycosylated Proteins
- Insulin
- Recombinant Human Growth Hormone
- Granulocyte Colony-stimulating Factor
- Filgrastim
- Pegfilgrastim
- Interferons
- Interferon-Beta
- Interferon-Alpha
- Recombinant Glycosylated Proteins
- Erythropoietin
- Monoclonal
Antibodies
- Adalimumab
- Bevacizumab
- Infliximab
- Rituximab
- Trastuzumab
- Other
Monoclonal Antibodies
- Follitropin
- Etanercept
- Recombinant Peptides
- Glucagon
- Calcitonin
Disease Type (Revenue, USD Million; 2016–2026)
- Oncology
- Blood Disorders
- Chronic Diseases
- Autoimmune Diseases
- Growth Hormone Deficiency
- Infectious Diseases
- Other Diseases
Regional Outlook (Revenue in USD Million;
2016–2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Browse More Reports of
Pharmaceutical Category At: https://www.reportsanddata.com/report/category/pharmaceutical
Contact
Us:
John Watson
Head of Business Development
Direct Line: +1-800-819-3052
No comments:
Post a Comment